Skip to content


Open Access

Transcription profiling of early responses to hemorrhagic fever in rhesus macaque

  • M Djavani1, 2,
  • O Crasta1, 2,
  • JC Zapata1, 2,
  • Z Fei1, 2,
  • O Folkerts1, 2,
  • B Sobral1, 2,
  • J Bryant1, 2,
  • C Pauza1, 2,
  • I Lukashevich1, 2 and
  • MS Salvato1, 2
Retrovirology20063(Suppl 1):P16

Published: 21 December 2006


AspirinGene Expression ChangeLethal DoseDisease TreatmentHemorrhagic Fever

Monkeys infected intravenously with a lethal dose of LCMV-WE provide a model for Lassa fever virus infection of man. Like Lassa fever in man, disease begins with flu-like symptoms and progresses rapidly to death within two weeks of infection. It is essential to correctly diagnose hemorrhagic fever rather than more benign viral diseases to provide the proper treatment. Microarray analyses were conducted on blood of macaques infected with virulent WE virus, and compared to gene expression in monkeys infected with non-virulent LCMV-ARM. We observed gene expression changes that occur before the viremic stage of the disease, and could potentially serve as biomarkers that discriminate between exposure to a hemorrhagic fever virus and exposure to a benign virus. In particular, transcription analysis revealed an early and severe suppression of the COX2 pathways indicating that disease treatments should avoid COX-inhibitors, like aspirin, and favor pathway stimulators.

Authors’ Affiliations

Institute of Human Virology, Baltechnology Institute, University of Maryland Biotechnology Institute, Baltimore, USA
Virginia Bioinformatics Institute, Blacksburg, USA


© Diavani et al; licensee BioMed Central Ltd. 2006

This article is published under license to BioMed Central Ltd.